Press Releases

April 21, 2014 Lupin Appoints Theresa Stevens as Chief Corporate Development Officer.

April 9, 2014 Lupin Receives FDA Approval for Generic Actos® Tablets.

March 27, 2014 Lupin Acquires Laboratorios Grin S.A. De C.V., Mexico; Specialty Ophthalmic Company; Enters the Latin American Market.

March 21, 2014 Lupin launches Generic Niaspan® Tablets in the US

March 6, 2014 Lupin Receives FDA Approval for Generic Monodox® Capsules and Cipro® for Oral Suspension

February 26, 2014 Lupin Receives FDA Approval for Generic Mycobutin® Capsules

February 18, 2014 Lupin Appoints Dr. Maurice Chagnaud as President-Europe & Head of Inhalation Strategy

February 3, 2014 Strong Growth, Record Profits Quarter III Results, FY 2013-14 Net Sales up 21%; EBITDA up 28%; Net profit up 42% Declares Interim Dividend of 150 %

February 3, 2014 Lupin Receives FDA Approval for Generic Mycobutin® Capsules